Russian Heart Failure Journal 2008year Chronic heart failure in women

To access this material please log in or register

Register Authorize

Chronic heart failure in women

Tereshchenko S. N., Zhirov I. V.



At present the need for special studies on gender peculiarities of CHF is above any doubt. Considering certain deficiency of data meeting criteria of evidence-based medicine in women special clinical and epidemiological studies are needed.
  1. Peterson S, Rayner M, Wolstenholme J. Coronary heart disease statistics: Heart failure supplement 2002 Edition. British Heart Foundation Health Promotion Research Group, Department of Public Health. University of Oxford, Health Economics Research Centre, Department of Public Health, University of Oxford.
  2. Lloyd-Jones D. The risk of congestive heart failure. Sobering lessons from the Framingham heart study. Curr Cardiol Rep. 2001; 3 (3):184‑190.
  3. Fox KF, Cowie MR, Coats AJS et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J. 2001; 22 (3):228‑236.
  4. Ho K, Anderson KM, Kannel WB et al. Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation. 1993; 88 (1):107‑115.
  5. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 1992; 20 (2):301‑306.
  6. Davies M, Hobbs F, Davis R et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet. 2001; 358 (9280):439‑444.
  7. Halm MA, Penque S. Heart failure in women. Prog Cardiovasc Nurs. 2000; 15 (4):121‑133.
  8. American Heart Association. Heart and Stroke Statistical Update. National Center, 7272 Greenville Avenue, Dallas, Texas. 2002:38.
  9. Riedinger M, Dracup K, Brecht ML. Quality of life in women with heart failure, normative groups, and patients with other chronic conditions. Am J Crit Care. 2002; 11 (3):211‑219.
  10. American Heart Association. Heart disease and Stroke Statistics – 2003. National Center, 7272 Greenville Avenue, Dallas, Texas, 2003.
  11. Levy D, Larson M, Vasan R et al. The progression from hypertension to congestive heart failure. JAMA. 1996; 275 (20):1557–1562.
  12. Hoffman R, Psaty BM, Kronmal RA. Modifiable risk factors for incidence of heart failure in the Coronary Artery Surgery Study. Arch Intern Med. 1994; 154 (4):417‑423.
  13. Chen YT, Vaccarino V, Williams CS et al. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med. 1999; 106 (6):605‑612.
  14. He J, Ogden LG, BazzanoLA et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001; 161 (7):996‑1002.
  15. Davis M. Impact of gender on drug responses. Drug Topics. 1998; 142:91‑100.
  16. Kannel WB, D’Agostino RB, Silbershatz H et al. Profile for estimating risk of heart failure. Arch Intern Med. 1999; 159 (11):1197–1204.
  17. Adams KF, Dunlap SH, Sueta CA et al. Relation between gender, etiology, and survival in patients with symptomatic heart failure. J Am Coll Cardiol. 1996; 28 (7):1781–1788.
  18. Opasich C, Tavazzi L, Lucci D et al. Comparison of one-year outcome in women versus men with chronic congestive heart failure. Am J Cardiol. 2000; 86 (3):353‑357.
  19. Simon T, Mary-Krause M, Funck-Bretano C et al. Sex differences in the prognosis of congestive heart failure. Results from the cardiac insufficiency bisoprolol study (CIBIS II). Circulation. 2001; 103 (3):375‑380.
  20. Benjamin E, Levy D, Vasiri S et al. Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham heart study. JAMA. 1994; 271 (11):840‑844.
  21. Benjamin EJ, Wolf PA, D’Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation. 1998; 98 (10):946‑952.
  22. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979; 241 (19):2035–2038.
  23. Ho KK, Pinsky JL, Kannel WB et al. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol. 1993; 22 (4 Suppl A):6A-13A.
  24. Lloyd-Jones D, Larson M, Leip E et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002; 106 (24):3068–3072.
  25. Urbano-Márquez A, Estruch R, Navarro-Lopez F et al. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med. 1989; 320 (7):409‑415.
  26. Fernández-Solà J, Estruch R, Nicolás JM et al. Comparison of alcoholic cardiomyopathy in women versus men. Am J Cardiol. 1997; 80 (4):481‑485.
  27. Jessup M, Pina I. Is it important to examine gender differences in the epidemiology and outcome of severe heart failure? J Thorac Cardiovasc Surg. 2004; 127 (5):1247–1252.
  28. Jochmann N, Stangl K, Garbe E et aL. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J. 2005; 26 (16):1585–1595.
  29. Shekelle PG, Rich MW, Morton SC et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003; 41 (9):1529–1538.
  30. Pfeffer MA, Swedberg K, Granger CB et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362 (9386):759‑766.
  31. Keyhan G, Chen S, Pilote L. Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure. Eur J Heart Fail. 2007l; 9 (6–7):594‑601.
  32. Hudson M, Rahme E, Behlouli H et al. Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure – a population study. Eur J Heart Fail. 2007; 9 (6–7):602‑609.
  33. Packer M, Lee WH, Medina N, et al. Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. J Am Coll Cardiol. 1987; 10 (6):1303–1311.
  34. Witchitz S, Haiat R, Tarrade T et al. Accidents cardio-vasculaires au cours des traitements par le verapamil: a propos de 6 observations. Nouv Presse Med. 1975; 4 (5):337‑338.
  35. Elkayam U, Weber L, McKay C et al. Spectrum of acute hemodynamic effects of nifedipine in severe congestive heart failure. Am J Cardiol. 1985; 56 (8):560‑566.
  36. Packer M, Lee WH, Medina N, Yushak M. Comparative negative inotropic effects of nifedipine and diltiazem in patients with severe left ventricular dysfunction. Circulation. 1985; 72: (Suppl III):III-275.
  37. Elkayam U, Amin J, Mehra A et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990; 82 (6):1954–1961.
  38. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991; 83 (1):52–60.
  39. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988; 319 (7):385‑392.
  40. Ferlinz J, Gallo CT. Responses of patients in heart failure to long-term oral verapamil administration. Circulation. 1984; 70: (Suppl II):II-305.
  41. Kloner RA, Sowers JR, DiBona GF et al. Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol. 1996; 77 (9):713‑722.
  42. Packer M, O`Connor C, Ghali J et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996; 335 (15):1107–1114.
  43. Bolland M, Barber P, Doughty R et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ. 2008; 336 (7638):262‑266.

To access this material please log in or register

Register Authorize
Ru En